DisitamabVedotinForIicction Toripalimab

PreclinicalMonoclonal antibody

DisitamabVedotinForIicction Toripalimab is one of 94 small molecule programs targeting Bladder Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bladder CancerRecruiting

Neoadjuvant TherapyRecruiting

Bladder CancerPreclinical

Recruiting

Neoadjuvant TherapyPreclinical

Recruiting

Competition

Competitive Landscape

99 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

53 2

Keytruda

Merck & Co.

Phase 3

28 3

Gemzar

Johnson & Johnson

Phase 3

23 4

Opdivo

Bristol-Myers Squibb

Phase 3

20 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

59 6

Tecentriq

Roche

Phase 3

15 7

Imfinzi

AstraZeneca

Phase 3

15 8

Trexall

Jazz Pharmaceuticals

Phase 3

12 9

Padcev

Pfizer

Phase 3

9 10

Imjudo

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Bladder Cancer

NCT06341400

Clinical

Trials by Indication[1]

Bladder Cancer1 trial

Perioperative Efficacy of RC48 Combined With Toripalimab in Treatment of Cisplatin Ineligible MIBC

Recruiting·ZZhujiang Hospital·Preclinical·NCT06341400·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DisitamabVedotinForIicction Toripalimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DisitamabVedotinForIicction Toripalimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DisitamabVedotinForIicction Toripalimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhujiang Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: ZZhujiang Hospital

DisitamabVedotinForIicction Toripalimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News